At the time of writing this article, I checked BioDelivery International Inc. (NASDAQ:BDSI) website and its latest SEC filings for any news related to the fact that Reckitt Benckiser Pharmaceuticals (RBP) has sued BDSI for filing a New Drug Application for BUNAVAIL, a lead product in BDSI's pipeline. I am surprised why BDSI has not informed their investors regarding this material event. With this new litigation, BDSI shares may put off some of the gains that were priced in over past several months in anticipation of a timely approval and/or securing a partner for BUNAVAIL.
About RBP: It's a part of ~$46B Reckitt Benckiser Group Plc (OTC:RBGPY), a manufacturer and marketer of branded products in...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|